PKBO | Peak Bio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0500 - 0.0700
52 Week Range	0.0020 - 0.2650
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	1,931
Average Volume	1,992
Shares Outstanding	23,124,900
Market Cap	1,618,743
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-03-15

Valuation
Profitability
Growth
Health
P/E Ratio	-0.39
Forward P/E Ratio	N/A
EPS	-0.18
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6
Country	USA
Website	PKBO

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

PKBO's peers: BIAFW

*Chart delayed

Analyzing fundamentals for PKBO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PKBO Fundamentals page.

Watching at PKBO technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PKBO Technicals page.